Chronic Kidney Disease (CKD) Clinical Trial
Official title:
The Impact of Vitamin D Supplementation on Vascular Stiffness and Blood Pressure in Chronic Kidney Disease Patients
Individuals with kidney disease have a high risk of heart disease. This is not related to traditional risk factors, such as high blood pressure, high cholesterol or being overweight. A lack of vitamin D could be the reason why blood vessels become damaged and could explain the link between heart disease and kidney disease.
Most people living in Canada do not receive enough vitamin D from the sun or from the food
they eat. When a person has kidney disease this is a particular problem as kidney disease
stops what little vitamin D we do have being activated in the body. Low levels of activated
vitamin D causes a domino effect with calcium and phosphate and all the hormones that
control calcium and phosphate. Some people believe that this imbalance damages the blood
vessels causing them to become stiff and inflexible (arterial stiffness) and this in turn
could cause heart disease. In addition there are two different types of vitamin D that can
be prescribed and it is currently not known whether there is any difference between the two
types of vitamin D and the effect they have on the blood vessels.
The purpose of this study is to investigate whether providing vitamin D as a medication can
have a direct affect on the stiffness of the blood vessels. The findings of this study will
help both physicians and dietitians decide whether Vitamin D therapy is beneficial to
patients and should help decide which type of Vitamin D is best to give to people with
chronic kidney disease (CKD).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05422755 -
The Clinical Study to Evaluate Immunogenicity of Epodion® in Anemia Associated With CKD Patients
|
||
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Recruiting |
NCT04064827 -
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02218099 -
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02276742 -
Lifestyle Management of CKD in Obese Diabetic Patients
|
N/A | |
Completed |
NCT01222234 -
Impact of Vitamin D Therapies on Chronic Kidney Disease
|
N/A | |
Recruiting |
NCT05106387 -
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive A Kidney Transplant
|
||
Completed |
NCT05373303 -
The Clinical Study for Evaluating The Safety And Efficacy Of Epodion®
|
N/A | |
Completed |
NCT04042350 -
Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis
|
||
Completed |
NCT02733328 -
Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury After Cardiac Surgery in Adults Study
|
||
Completed |
NCT02341664 -
Patient and Provider Assessment of Lipid Management Registry
|
||
Enrolling by invitation |
NCT06322641 -
A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists
|
||
Completed |
NCT05755373 -
A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Cardiologists
|
||
Completed |
NCT02678000 -
Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function
|
Phase 2 | |
Completed |
NCT02185911 -
Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis
|
N/A | |
Terminated |
NCT03226899 -
A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
|
Phase 4 | |
Completed |
NCT02504294 -
A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
Active, not recruiting |
NCT04094831 -
Community-based Screening of Chronic Kidney Disease (CKD) and Measure the Impact of Health Education
|
N/A | |
Completed |
NCT01810939 -
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
|
Phase 3 | |
Enrolling by invitation |
NCT06447038 -
Pilot Study for the Early Detection of Chronic Kidney Disease, Non-Dialysis Objective (NDO).
|